Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, T.; K. Kumar, Shaji; Plesner, T.; Orlowski, R.; Moreau, P.; Bahlis, N.; Basu, S.; Nahi, H.; Hulin, C.; Quach, H.; Goldschmidt, H.; O'Dwyer, M.; Perrot, A.; Venner, C.; Weisel, K.; Mace, J.; Raje, N.; Attal, M.; Tiab, M.; Macro, M.; Frenzel, L.; Leleu, X.; Ahmadi, T.; Chiu, Christopher; Wang, Jianping; Van Rampelbergh, R.; Uhlar, C.; Kobos, R.; Qi, M.; Usmani, S.

doi:10.1056/NEJMoa1817249

Public

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Shared by NobleBlocks on May 29, 2019 • 12:00 AM UTC

Authors:

T. Facon

Shaji K. Kumar

T. Plesner

Abstract

BACKGROUND Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether the addition of daratumumab would significantly reduce the risk of disease progression or ...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!